The association between JAK2V617F mutation and bone marrow fibrosis at diagnosis in patients with philadelphia-negative chronic myeloproliferative neoplasms Philadelphia Negatif Kronik Miyeloproliferatif Neoplazili Hastaların Tanısında JAK2V617F Mutasyonu ile Kemik İliǧindeki Fibrozun İlişkisi

Creative Commons License

Ar M. C., Buyuktas D., Eskazan A. E., Aydin S. O., Tanrikulu E., Baslar Z., ...Daha Fazla

Turkish Journal of Hematology, cilt.29, sa.3, ss.242-247, 2012 (SCI-Expanded, Scopus, TRDizin) identifier identifier identifier

Özet

Objective: Bone marrow fibrosis is the second most common complication that causes morbidity and mortality in patients with Philadelphia-negative myeloproliferative neoplasms (MPNs). The aim of this study was to investigate the association between JAK2V617F mutation and bone marrow fibrosis at diagnosis in patients with MPNs. Material and Methods: In total, 149 patients with MPNs were retrospectively evaluated to determine if there was an association between the histological grade of bone marrow fibrosis and JAK2V617F mutation. Results: In all, 67.7% of the patients carried the mutated JAK2 gene. The presence of JAK2V617F mutation was not associated with the occurrence of bone marrow fibrosis (P = 0.552) or its grade at diagnosis (P = 0.65). Conclusion: Molecular mechanisms or genetic defects other than JAK2V617F may underlie the occurrence of bone marrow fibrosis in patients with MPNs.